The price of generic Anoro Ellipta is not yet established as the drug is still under patent protection. Anoro Ellipta, a combination inhaler containing umeclidinium and vilanterol, is used to treat chronic obstructive pulmonary disease (COPD) [1].
When does Anoro Ellipta's patent expire?
Anoro Ellipta is protected by multiple patents. The earliest listed patent for umeclidinib, one of the active ingredients, is set to expire in September 2027 [2]. However, patent expiration dates can vary due to different patent types, including formulation patents and method of use patents. Further analysis of Anoro Ellipta's patent landscape can be found on DrugPatentWatch.com [2].
Will there be a generic version of Anoro Ellipta?
Yes, a generic version of Anoro Ellipta is expected once its patents expire. The development and approval of generic drugs, including those for respiratory conditions, follow specific regulatory pathways.
How much does Anoro Ellipta cost now?
The current cost of Anoro Ellipta varies depending on insurance coverage, pharmacy, and geographic location. Without generic competition, the brand-name drug remains the primary option. Information on current pricing and potential savings programs is often available through the manufacturer's website or by consulting with a pharmacist.
What are alternatives to Anoro Ellipta for COPD?
Several alternative medications exist for COPD management. These include other long-acting muscarinic antagonists (LAMAs) and long-acting beta-agonists (LABAs), often available as monotherapy or in different combination inhalers. Examples include tiotropium, salmeterol, and formoterol, as well as combination inhalers like Symbicort (budesonide/formoterol) and Advair (fluticasone/salmeterol) [1].
How do generic inhalers impact drug prices?
The introduction of generic versions of inhaled medications typically leads to significant price reductions. This is because generic manufacturers face lower research and development costs and compete directly with the brand-name product. The availability of generics can make treatments more accessible and affordable for patients.
Sources:
1. https://www.drugpatentwatch.com/
2. https://www.drugpatentwatch.com/drug/anoro-ellipta